Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of exatecan mesylate in treating patients who have advanced solid tumors and kidney dysfunction.

Key facts

Study ID

NCT00045318

Run by

Jonsson Comprehensive Cancer Center

Starts

2002-05-01

Expected to finish

2007-10-01

Last updated by the study team

2013-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• Brooke Army Medical Center — Fort Sam Houston, Texas, United States
• Cancer Therapy and Research Center — San Antonio, Texas, United States
• St. Luke's Lutheran Hospital — San Antonio, Texas, United States
• Veterans Affairs Medical Center - San Antonio (Murphy) — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.